Please see below for a list of search results.
The Human Tissue Authority is committed to promoting equality and diversity, both as an employer and in the carrying out of its public functions to monitor and promote good practice in the sectors that it regulates.
Accuracy of informationPlease note the following: Every effort has been made to ensure that the information provided on this website is accurate, but accuracy cannot be guaranteed and the information provided does not constitute legal or other professional advice.
DIs and LHs both play key roles in the licensing arrangements under the Human Tissue Act (2004) and the Q&S Regulations. This section explains the roles and responsibilities of these individuals under the Q&S Regulations. Separate guidance is available on the role of Designated...
Umbilical cord blood may be collected at the time of birth and stored, so that it is available for potential future treatment of the child or another person.
It is a mandatory requirement that the processes used to prepare tissue or cells for patient treatment (human application) do not render them clinically ineffective or harmful, and they must be validated.
The validation of the processes may be based on:
Procurement is defined as the processes by which tissues and cells are made available, including the physical act of removing tissue and the donor selection and evaluation.
This guide explains the regulatory requirements for establishments in the Human Application sector.
The Human Fertilisation and Embryology Authority (HFEA) and the Human Tissue Authority (HTA) have been working together to reduce the regulatory overlap regarding the storage of ovarian and testicular tissue.